Summary
109.76 -0.42(-0.38%)10/04/2024
Merck & Co Inc (MRK)
Merck & Co Inc (MRK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.35 | -3.46 | -5.21 | -13.21 | -14.02 | 7.43 | 49.38 | 154,864.77 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 109.76 | |
| Open | 109.49 | |
| High | 110.30 | |
| Low | 109.39 | |
| Volume | 7,180,858 | |
| Change | -0.38 | |
| Change % | -0.35 | |
| Avg Volume (20 Days) | 6,440,078 | |
| Volume/Avg Volume (20 Days) Ratio | 1.12 | |
| 52 Week Range | 99.14 - 134.63 | |
| Price vs 52 Week High | -18.47% | |
| Price vs 52 Week Low | 10.71% | |
| Range | 0.25 | |
| Gap Up/Down | -2.59 | |
Fundamentals | ||
| Market Capitalization (Mln) | 286,662 | |
| EBIDTA | 21,211,000,832 | |
| PE Ratio | 144.5111 | |
| PEG Ratio | 0.1008 | |
| WallStreet Target Price | 141.42 | |
| Book Value | 15.9370 | |
| Earnings Per Share | 0.9000 | |
| EPS Estimate Current Quarter | 1.8700 | |
| EPS Estimate Next Quarter | 2.1600 | |
| EPS Estimate Current Year | 8.6600 | |
| EPS Estimate Next Year | 9.9900 | |
| Diluted EPS (TTM) | 0.9000 | |
| Revenues | ||
| Profit Marging | 0.0376 | |
| Operating Marging (TTM) | 0.4247 | |
| Return on asset (TTM) | 0.1026 | |
| Return on equity (TTM) | 0.0531 | |
| Revenue TTM | 61,403,000,832 | |
| Revenue per share TTM | 24.2150 | |
| Quarterly Revenue Growth (YOY) | 0.0890 | |
| Quarterly Earnings Growth (YOY) | 0.6850 | |
| Gross Profit (TTM) | 42,077,000,000 | |
| Dividends | ||
| Dividend Share | 2.9600 | |
| Dividend Yield | 0.0237 | |
| Valuations | ||
| Trailing PE | 144.5111 | |
| Forward PE | 14.6843 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.4751 | |
| Revenue Enterprise Value | 5.7634 | |
| EBITDA Enterprise Value | 50.1614 | |
| Shares | ||
| Shares Outstanding | 2,532,809,984 | |
| Shares Float | 2,527,943,319 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.05 | |
| Institutions (%) | 77.99 | |
10/05 09:00 EST - seekingalpha.com
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.4%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.4%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.
10/05 05:25 EST - fool.com
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices.
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices.
10/05 02:38 EST - seekingalpha.com
Buy 2 October Dogs Of The Dow And Watch 5 More
"The Dow® [adds a stock] if the company has an excellent reputation,
Buy 2 October Dogs Of The Dow And Watch 5 More
"The Dow® [adds a stock] if the company has an excellent reputation,
10/04 10:27 EST - marketbeat.com
3 Bargain Stocks Positioned for Gains After Missing 2024's Rally
By most accounts, the stock market has had a very good 2024. The S&P 500 has provided a total return so far of 20.6%.
3 Bargain Stocks Positioned for Gains After Missing 2024's Rally
By most accounts, the stock market has had a very good 2024. The S&P 500 has provided a total return so far of 20.6%.
10/03 08:11 EST - 247wallst.com
3 Top Pharma Stocks to Buy in October 2024
The pharmaceutical industry plays a crucial role in most of our everyday lives.
3 Top Pharma Stocks to Buy in October 2024
The pharmaceutical industry plays a crucial role in most of our everyday lives.
10/01 13:16 EST - zacks.com
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
10/01 06:45 EST - businesswire.com
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. “By actively depleting B-cells, CN201 offers applications spanning both B-cell malignancies and autoimmune diseases. We look forward to building upon the foundational work started by the Cur.
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. “By actively depleting B-cells, CN201 offers applications spanning both B-cell malignancies and autoimmune diseases. We look forward to building upon the foundational work started by the Cur.
10/01 06:30 EST - businesswire.com
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31.
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31.
09/29 06:28 EST - fool.com
Is Merck Stock a Buy?
Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years.
Is Merck Stock a Buy?
Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years.
09/26 18:56 EST - zacks.com
Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
09/26 13:20 EST - zacks.com
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
09/26 06:45 EST - businesswire.com
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in ulcerative colitis (UC) and Crohn's disease (CD) will be presented at the United European Gastroenterology (UEG) Week 2024 Congress in Vienna, Austria. Long-t.
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in ulcerative colitis (UC) and Crohn's disease (CD) will be presented at the United European Gastroenterology (UEG) Week 2024 Congress in Vienna, Austria. Long-t.
09/25 10:30 EST - gurufocus.com
When Buffett Meets Bannister
Barry Bannister, Managing Director and Chief Equity Strategist at Stifel, put out an excellent research piece on future returns based on what industry folks call the “equity risk premium.” He says that investors in U.S. common stocks are looking forward to no more than a 3% real return over the next decade from the S&P 500 Index and shows his reasoning in the following chart:
When Buffett Meets Bannister
Barry Bannister, Managing Director and Chief Equity Strategist at Stifel, put out an excellent research piece on future returns based on what industry folks call the “equity risk premium.” He says that investors in U.S. common stocks are looking forward to no more than a 3% real return over the next decade from the S&P 500 Index and shows his reasoning in the following chart:
09/25 07:24 EST - marketwatch.com
Merck says trial of combination treatment for colon cancer failed to meet main goal
Merck & Co.'s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.
Merck says trial of combination treatment for colon cancer failed to meet main goal
Merck & Co.'s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.
09/25 06:59 EST - reuters.com
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
09/25 06:45 EST - businesswire.com
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC.
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC.
09/25 06:30 EST - businesswire.com
Merck's KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Receives New Approvals in Japan for Certain Patients With NSCLC and Radically Unresectable Urothelial Carcinoma.
Merck's KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Receives New Approvals in Japan for Certain Patients With NSCLC and Radically Unresectable Urothelial Carcinoma.
09/23 10:56 EST - zacks.com
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
09/20 10:56 EST - zacks.com
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.
09/20 07:30 EST - businesswire.com
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Gynecologic Cancers.
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Gynecologic Cancers.